Global analysis of actionable genomic alterations in thyroid cancer and precision-based pharmacogenomic strategies
This study underscores the significance of integrating genomic insights with pharmacogenomic strategies to address disparities in thyroid cancer treatment. The identification of population-specific oncogenic variants and actionable therapeutic targets provides a foundation for advancing precision oncology. Future efforts should focus on including underrepresented populations, developing population-specific prevention strategies, and fostering global collaboration to ensure equitable access to pharmacogenomic testing and innovative therapies. These initiatives have the potential to transform thyroid cancer care and align with the broader goals of personalized medicine.
Authors
- Gabriela Echeverría‐Garcés (ORCID: https://orcid.org/0000-0002-1941-7864)
- Andrés López‐Cortés (ORCID: https://orcid.org/0000-0003-1503-1929)
- Sebastián Rivera-Orellana (ORCID: https://orcid.org/0009-0003-3119-9817)
- Samantha Espinoza-Ferrao
- José Bueno‐Miño
- Emilia Castellanos-Molina
- Melanie Benítez-Núñez
Institutions
- Universidad de Las Américas (EC)
- Instituto Nacional de Investigación en Salud Pública (EC)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fphar.2025.1524623
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00